Due to payments from drug development partner AstraZeneca, Targacept, a biopharmaceutical company located in Winston-Salem, recorded profitability for 2010. Targacept reported a net income of nearly $11M, which was roughly a $50M turnaround from 2009.
Targacept, Inc. is focused on the development of a new type of drugs, NNR Therapeutics, for the treatment of diseases and disorders of the nervous system. (targacept.com)
Targacept, Inc. joined the CED community in 2004 and has sponsored CED’s Biotech Life Science conference for the past 6 years. Jeffrey Brennan, a Senior Vice President, is also speaking at this year’s conference during the Entrepreneur Workshop.
No comments:
Post a Comment